Press Releases and Statements

CHPA expresses its gratitude to New Jersey's governor, senator, and assembly members for shepherding the bill through the legislature. CHPA has long supported state efforts to curb teen OTC cough medicine abuse.

CHPA released the following statement in response to an article in Pediatrics, the official journal of the American Academy of Pediatrics, which reported a decline in emergency department visits for unsupervised medication exposures in young children.

CHPA is pleased to lend its strong support for the DXM Abuse Prevention Act of 2015 (H.R. 3250), introduced into the U.S. House of Representatives by U.S. Reps. Bill Johnson (R-OH) and Doris Matsui (D-CA).

CHPA highlights the results of a recent five-state survey from the Asthma and Allergy Foundation of America, which found that consumers on the whole, prefer full access to OTC medicine containing pseudoephedrine.

The Consumer Healthcare Products Association today issued the following statement in response to the Food and Drug Administration’s Drug Safety Communication on non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs).

CHPA applauds the Energy and Commerce Committee on House passage of the 21st Century Cures initiative. CHPA looks forward to the implementation of these provisions and believes it will help accelerate the discovery, development, and delivery of new treatments and cures for patients

CHPA released the following statement in support of today’s enactment of a Washington State law prohibiting the sale of OTC medicines containing the cough suppressant dextromethorphan (DXM) to minors.

Designed to expand the knowledge of industry professionals, OTC Academy will provide a comprehensive overview of business-critical topics through three different learning formats, including e-learning, seminars, and workshops.

Consumer Healthcare Products Association President and CEO Scott Melville released the following statement today regarding this afternoon’s hearing on microbeads legislation.

The five associations representing the dietary supplement industry have requested that FDA issue revised guidance on new dietary ingredient (NDI) notifications, with a specific focus on the information to be included to identify the new dietary ingredient.